{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'LIST OF ABBREVIATIONS (Amended 19 October 2018)', 'A. baumannii', 'Acinetobacter baumannii', 'AE', 'Adverse Event', 'AECOPD', 'Acute exacerbation of COPD', 'ATS-DLD-78A', 'American Thoracic Society-Division of Lung Diseases-', '78A', 'CAT', 'COPD assessment test', 'CI', 'Confidence Interval', 'CLS', 'Clinical Laboratory Sciences', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'DTT', 'Dithiothreitol', 'eCRF', 'electronic Case Report Form', 'EoS', 'End of Study', 'ER', 'Emergency Room', 'EXACT-PRO', 'Exacerbations of Chronic Pulmonary Disease Tool -', 'Patient Reported Outcome', 'FAS', 'Full Analysis Set', 'FEV1', 'Forced expiratory volume in 1 second', 'FVC', 'Forced vital capacity', 'GCP', 'Good clinical practice', 'GOLD', 'Global Initiative for Chronic Obstructive Lung Disease', 'GP', 'General Practitioner', 'GSK', 'GlaxoSmithKline', 'H. influenzae', 'Haemophilus influenzae', 'HRQOL', 'Health-related quality of life', 'HRV', 'Human Rhinovirus', '19-OCT-2018', '20', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'ICD', 'International Classification of Diseases', 'ICF', 'Informed Consent Form', 'ICH', 'International Conference on Harmonisation', 'IEC', 'Independent Ethics Committee', 'IRB', 'Institutional Review Board', 'K. pneumoniae', 'Klebsiella pneumoniae', 'LAR', 'Legally Acceptable Representative', 'M. catarrhalis', 'Moraxella catarrhalis', 'OTC', 'Over-the-counter', 'P. aeruginosa', 'Pseudomonas aeruginosa', 'PCD', 'Primary Completion Date', 'PCR', 'Polymerase chain reaction', 'RSV', 'Respiratory syncytial virus', 'RT-PCR', 'Reverse transcription polymerase chain reaction', 'S. aureus', 'Staphylococcus aureus', 'S. pneumoniae', 'Streptococcus pneumoniae', 'SAE', 'Serious Adverse Event', 'SGRQ-C', \"St. George's Respiratory Questionnaire for COPD\", 'patients', 'SPM', 'Study Procedures Manual', 'USA', 'United States of America', '19-OCT-2018', '21', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'GLOSSARY OF TERMS', 'Adverse event:', 'Any untoward medical occurrence in a subject,', 'temporally associated with the use of a medicinal product,', 'whether or not considered related to the medicinal', 'product, or temporally associated with a study procedure.', 'An adverse event (AE) can therefore be any unfavourable', 'and unintended sign (including an abnormal laboratory', 'finding), symptom, or disease (new or exacerbated)', 'temporally associated with the use of a medicinal product.', 'For marketed medicinal products, this also includes', 'failure to produce expected benefits (i.e., lack of', 'efficacy), abuse or misuse.', 'Anonymised data:', 'Information about an individual that GSK or a third party', 'cannot reasonably attribute to the individual, or could', 'only attribute to the individual by expending a', 'disproportionate amount of time, effort or expense (e.g.', 'de-identified or aggregated information). For the purpose', 'of this policy, Key-Coded personally identifiable', 'information shall not be considered Anonymised', 'Information', 'Current smoker', 'A person who is currently smoking or who stopped', 'smoking within the past 6 months.', 'Cohort study:', 'A form of epidemiological study where subjects in a', 'study population are classified according to their', 'exposure status/disease and followed over time', 'prospective/ retrospective) to ascertain the outcome(s).', 'Eligible:', 'Qualified for enrolment into the study based upon strict', 'adherence to inclusion/exclusion criteria.', 'Epidemiological study:', 'An observational or interventional study without', 'administration of medicinal product(s) as described in a', 'research protocol.', '19-OCT-2018', '22', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']\n\n###\n\n", "completion": "END"}